BLA 761151 · Ucb INC
Bimzelx
Bimekizumab-Bkzx · Injection
NovelCDER novel approval, Oct 17, 2023: To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Last checked: Nov 20, 2026Latest source record: Nov 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 17, 2023
Approved uses
6
Original approval plus efficacy supplements
Registered trials
56
25 Phase 3, 9 recruiting
FAERS reports
26,321
8,343 serious, 184 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2026.
BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 ) 1.1 Plaque Psoriasis BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis BIMZELX is indicated for the treatment of adults with active psoriatic arthritis. 1.3 Non-Radiographic Axial Spondyloarthritis BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. 1.4 Ankylosing Spondylitis BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis. 1.5 Hidradenitis Suppurativa BIMZELX is indicated for the treatment of adults with moderate to severe hidradenitis suppurativa.
Mechanism: Bimekizumab-bkzx is a humanized immunoglobulin IgG1/ κ monoclonal antibody with two identical antigen binding regions that selectively bind to human interleukin 17A (IL-17A), interleukin 17F (IL-17F), and interleukin 17-AF cytokines, and inhibits their interaction with the IL-17 receptor complex. IL-17A and IL-17F are naturally occurring cytokines that are involved in normal inflammatory and immune responses. Bimekizumab-bkzx inhibits the release of proinflammatory cytokines and chemokines.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 19, 2024 Supplement 10 · Efficacy LabelLetterReview
- Oct 11, 2024 Supplement 9 · Efficacy LabelMedication GuideLetter
- Sep 20, 2024 Supplement 7 · Efficacy LabelLetterReview
- Sep 20, 2024 Supplement 5 · Efficacy LabelLetterReview
- Sep 20, 2024 Supplement 6 · Efficacy LabelLetterReview
- Oct 17, 2023 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelLetterLabelReview
1 products under this application
- BIMZELX · BIMEKIZUMAB-BKZX 160ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bimekizumab" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
NCT03598790 · 1,353 participants · Start Sep 5, 2018 · Primary completion Nov 14, 2023
Drug: Bimekizumab · For: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis
Sites: Glendale, Arizona; Phoenix, Arizona; Bakersfield, California · 189 sites in all
- A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisPivotal-lookingCompleted
NCT04009499 · 1,131 participants · Start Aug 13, 2019 · Primary completion May 26, 2026
Drug: Bimekizumab · For: Psoriatic Arthritis
Sites: Phoenix, Arizona; San Diego, California; Palm Harbor, Florida · 138 sites in all
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisPivotal-lookingCompleted
NCT03895203 · 852 participants · Start Apr 3, 2019 · Primary completion Aug 17, 2021
Drug: Bimekizumab; Adalimumab · For: Psoriatic Arthritis
Sites: Phoenix, Arizona; San Diego, California; Tustin, California · 136 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
NCT03536884 · 743 participants · Start Jun 13, 2018 · Primary completion Sep 12, 2019
Drug: Bimekizumab; Secukinumab · For: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis
Sites: Santa Ana, California; Danbury, Connecticut; Ocala, Florida · 77 sites in all
- A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04901195 · 658 participants · Start May 27, 2021 · Primary completion Jul 22, 2026
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Fountain Valley, California · 145 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisPivotal-lookingCompleted
NCT03370133 · 567 participants · Start Dec 6, 2017 · Primary completion Jan 8, 2019
Drug: Bimekizumab; Ustekinumab · For: Chronic Plaque Psoriasis; Moderate to Severe Chronic Plaque Psoriasis; Psoriatic Arthritis
Sites: Phoenix, Arizona; Bakersfield, California; San Diego, California · 105 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisPivotal-lookingCompleted
NCT06624228 · 553 participants · Start Oct 21, 2024 · Primary completion Feb 6, 2026
Drug: Bimekizumab; Risankizumab and 1 more · For: Psoriatic Arthritis
Sites: Gilbert, Arizona; Glendale, Arizona; Phoenix, Arizona · 127 sites in all
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingCompleted
NCT04242498 · 509 participants · Start Mar 2, 2020 · Primary completion Nov 9, 2021
Drug: Bimekizumab · For: Hidradenitis Suppurativa
Sites: Fountain Valley, California; Thousand Oaks, California; Miami, Florida · 91 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue4,798
- psoriasis3,204
- drug ineffective2,544
- off label use2,157
- hidradenitis2,041
- condition aggravated1,885
- psoriatic arthropathy1,876
- injection site pain1,487
- inappropriate schedule of product administration1,205
- therapy interrupted1,187
- pruritus1,119
- pain1,096
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 13 |
| 2023 | 126 |
| 2024 | 2,720 |
| 2025 | 10,928 |
| 2026 | 12,523 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bimzelx (Bimekizumab-Bkzx)
2024 spending
$7.6M
Beneficiaries
134
509 claims
Per beneficiary
$56,469
$7,220.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $299,437 |
| 2024 | $7,566,799 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, et al. · Lancet 2024 · Randomized Controlled Trial, Multicenter Study
- Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K, Warren RB, Lebwohl M, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB, Blauvelt A, Bagel J, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2025 · Comparative Study, Network Meta-Analysis
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.